Multiple sclerosis (MS) is a chronic inflammatory disease pftem potentially disabling, demyelinating and neurodegenerative of the brain and spinal cord in young adults. This disorder is a heterogeneous, multifactorial, immune-mediated disease that is influenced by both genetic and environmental factors. Multiple sclerosis symptoms could be differing greatly in patients and over the course of the disease depending on the location and the amount of damage in affected nerve fibers. MS symptoms include visual impairments, tingling and numbness, episodic bouts of fatigue, intestinal and urinary system disorders, spasticity, and learning and memory impairment.
Panel test:
● Oligoclonal Band in CSF and Serum
o IgG – serum, CSF, index
o Albumin – CSF, serum by nephelometry, index
o CSF – IgG/albumin ratio, IgG synthesis rate, OCBs
● Aquaporin-4 Receptor Antibody: Aid in evaluation of Neuromyelitis optica (NMO) and NMO spectrum disorders
● Anti- myelin oligodendrocyte glycoprotein (MOG)
● Interferon Beta Neutralizing Antibody
● Natalizumab Antibodies
Reference:
1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BM, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162-173. PubMed
